Use of anti-ferritin monoclonal antibodies in the treatment of some cancers
View Patent ↗The invention concerns the use, in the preparation of a medicine for treating cancer whereof the cells exhibit overexpression of a product of a gene of the myc-related family, of an anti-ferritin monoclonal antibody or a fragment thereof, said antibody or said fragment identifying an epitope common to acidic and basic human ferritins.
1. A method for in vivo targeting a molecule X to tumours or tumour cells which exhibit an overexpression of the product of a gene from the myc family, in a human having said tumour or tumour cells, said method comprising:
a. providing an antiferritin monoclonal antibody or a fragment thereof, said antibody or said fragment recognizing an epitope that is common to acidic and basic human ferritins, and has an affinity of more than 10 −9 mole/liter;
b. coupling said antibody or fragment thereof to said molecule X to provide a coupling product; and,
c. administering said coupling product to a human in vivo;
wherein said, antiferritin monoclonal antibody or fragment thereof targets molecule X to said tumour or tumour cells which exhibit an overexpression of the product of a gene from the myc family via binding of said monoclonal antibody or fragment thereof to said tumour or tumour cells.
2. The method of claim 1 , wherein said epitope that is common to acidic and basic human ferritins is repetitive.
3. The method of claim 1 , wherein said antiferritin monoclonal antibody is an IgG.
4. The method of claim 1 , wherein the monoclonal antibody is an IgM or a fragment thereof.
5. The method of claim 1 , wherein X is a beta-emitting radioisotope.
6. The method of claim 1 , wherein X is a toxic molecule.
7. The method of claim 6 , wherein said toxic molecule X is selected among the group of the A chain ricin or abrin type, A chain diphteria toxin and a cytolytic substance of the methotrexate, mitomycin, taxol or adriamycin type.
8. The method of claim 1 , wherein X is a cytostatic and/or cytotoxic antisense RNA.
9. The method of claim 1 , wherein X is a substance stabilized by a liposome type vector.
10. The method of claim 1 , wherein X is an antibody recognizing a specific receptor of a tumour cell.
11. The method of claim 1 , wherein X is an antibody recognizing an antigen of lymphoid, dendritic, macrophagic or natural killer type cells.
12. The method of claim 1 , wherein X is an alpha-emitting radioisotope.
13. The method of claim 1 , wherein X is a gamma-emitting radioisotope.
14. The method of claim 1 , wherein a C5 to C15 spacer is integrated into the coupling product and can liberate the X molecule when the coupling product is brought into the presence of esterase.
15. A method to determine or localize in an individual the presence of a tumour or cancerous cells in which the product of gene from the myc family is overexpressed, comprising:
a. providing an antiferritin monoclonal antibody or a fragment thereof, said antibody or said fragment recognizing an epitope that is common to acidic and basic human ferritins, and has an affinity of more than 10 −9 mole/liter;
b. coupling directly or indirectly said antibody or fragment thereof to a signal emitting substance to provide a coupling product;
c. administering said coupling product to an individual in vivo; and,
d. localizing tumour or cancerous cells by detecting the signal emitted by said coupling product.
16. The method of claim 15 , wherein said epitope common to acidic and basic human ferritins is repetitive.
17. The method of claim 15 , wherein said antibody or fragment thereof is coupled to a beta-emitting yttrium-90 type.
18. The method of claim 15 , wherein the antibody is coupled to a substance emitting a fluorescent or luminescent signal.
19. The method of claim 15 , wherein the antiferritin monoclonal antibody is an IgG.